Chiesi is International Group, headquartered in Parma, Italy, is engaged in research in the field of pharmaceuticals and healthcare, is represented in 30 countries and has more than 85 years of experience in the pharmaceutical sector. To make its mission to improve the quality of people's lives a reality, Chiesi conducts research, develops and provides innovative drugs for three therapeutic areas: AIR (goods and services that improve the breathing of people of any age, from newborns to adults), RARE (treatment of rare and very rare diseases) and CARE (products and services that help medical professionals provide special care, and consumers — take care of themselves). Since 2019, the Chiesi Group has been the world's largest pharmaceutical company with a B Corp. certificate. In 2018, Chiesi Pharmacheutici S. P. A. changed its legal status to a "benefit corporation", which allows it to pursue a dual goal: not only to create value for shareholders and businesses, but also to have a positive impact on society and the environment. The global B Corp movement sees business as a means to achieve the public good. The Group of Companies has also committed to achieving zero greenhouse gas emissi ons by the end of 2035.